The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
The CAR T-cell product axicabtagene ciloleucel (axi-cel) has become established as a successful treatment for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The efficacy and safety of axi-cel as a frontline treatment for high-risk LBCL is being investigated in the ZUMA-12 phase II clinical trial (NCT03761056). Interim study results have been previously reported by The Lymphoma Hub. Here, we summarize results from the primary analysis, published by Neelapu, et al., in Nature Medicine.1
The study is a multicenter, open-label, single-arm, phase II trial in adult patients with high-grade confirmed LBCL. High grade was defined as the presence of MYC and BCL2 and/or BCL6 translocations, or an International Prognostic Index ≥3 at any time prior to enrolment. Further information on the study design can be found here.
Table 1. Key patient baseline characteristics in ZUMA-12*
DA-EPOCH-R, etoposide phosphate, prednisone, vincristine sulphate (Oncovin), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), and rituximab; ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; IPI, International Prognostic Index; R-CHOP, rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone. |
|
Baseline characteristic, n (%) |
N = 40 |
---|---|
Median age (range), years |
61 (23–86) |
≥65 years |
15 (38) |
Male |
27 (68) |
Disease stage III–IV |
38 (95) |
ECOG Performance Status ≥1 |
25 (63) |
One prior systemic line |
32 (100) |
Double- or triple-hit only |
6 (15) |
Double- or triple-hit and IPI ≥3 |
4 (10) |
IPI ≥3 only |
20 (50) |
Deauville score |
|
4 |
19 (48) |
5 |
21 (53) |
Alterations by FISH |
|
MYC |
19 (48) |
BCL2 |
15 (38) |
BCL6 |
10 (25) |
Previous systemic therapy |
|
R-CHOP |
19 (48) |
DA-EPOCH-R |
18 (45) |
Neither R-CHOP nor DA-EPOCH-R |
6 (15) |
Table 2. Most common Grade ≥3 adverse events in patients receiving axi-cel*
*Data from Neelapu, et al.1 |
|
Adverse event, n (%) |
N = 40 |
---|---|
Neutropenia |
5 (13) |
Reduced neutrophil count |
21 (53) |
Reduced white cell count |
17 (43) |
Anemia |
12 (30) |
Encephalopathy |
6 (15) |
Thrombocytopenia |
6 (15) |
Hypoxia |
5 (12) |
Considering biomarkers and CAR T-cell levels:
No statistical significance was found between median peak levels of CAR T-cells in patients who relapsed/did not respond, and those who had an ongoing response to axi-cel. Several cytokines were found to be at least doubled in patients who experienced Grade ≥3 neurological events, including interleukin (IL)-5, macrophage inflammatory protein-1α (MIP-1α), interferon (IFN)-γ, granulocyte-macrophage colony-stimulating factor (GM-CSF), ferritin, tumor necrosis factor (TNF)-α, IL-10, IL-8, and programmed death-ligand 1 (PDL1) (p < 0.05).
The primary analysis of the ZUMA-12 phase II trial suggests that axi-cel has potential as a safe and effective option for the frontline treatment for high-grade LBCL. In the cohort of 37 efficacy-evaluable patients, objective response rate and complete response rate were 89% and 78%, respectively, and CAR T-cell expansion was observed in all participants. Safety data is comparable to other studies using axi-cel, with manageable adverse events and toxicities. Larger, randomized control studies are needed to replicate these results in large study populations and further compare efficacy and safety data with current standard-of-care treatment.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content